Trial Profile
A Single Arm, Open-label, Phase II Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Proof of concept; Therapeutic Use
- Acronyms RUBY
- 24 Nov 2021 Primary endpoint has not been met (Clinical Benefit Rate) , according to Results published in the European Journal of Cancer
- 24 Nov 2021 Results published in the European Journal of Cancer
- 05 Jun 2021 Status changed from active, no longer recruiting to completed.